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Abstract. Amplification and mutation of Ha-ras has been 
shown to correlate with the malignancy of tumors that appear in 
chemically-induced mouse skin. Cell lines isolated from mouse 
skin tumors represent the evolutionary stages of tumor 
development. Due to the high Ha-ras levels the JNK and ERK 
modules are found elevated, contributing to the enhanced AP-1 
activity in the more malignant cells. To examine the role of the 
transforming Ha-ras in controlling ERK signaling, transection 
of an activated Ha-ras allele was tested in a squamous cell 
carcinoma cell line. The ERK1/2 signaling pathways were 
blocked pharmacologically by PD98059 MEK inhibitor, which 
inhibited cell proliferation and anchorage-independent growth of 
squamous and spindle carcinoma cells. In addition, treatment 
with PD98059 and introduction of the dominant negative ATE-2 
mutant into the spindle carcinoma cells, partially reverted the 
spindle phenotype to squamous - like. These results suggest that 
ERK1/2 and ATE-2 play an important role in oncogenicity and 
in the degree of progression within the mouse skin carcinogenesis 
system. 
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1. Introduction 
Mutations of the ras family of proto-oncogenes are present in 
30% of human tumors, contributing to the development of 
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cancer. They are also involved in tumor development in 
rodents (1). The Ras family of small GTPases are regulated 
by extracellular signals, such as growth factors, which lead 
to an increase in GTP-bound Ras (2,3). A major Ras 
effector is the Raf-1 serine/threonine kinase, which is 
activated by binding to the GTP-bound state of p21Ras. 
The activation of the ERK family of MAPKs, via Raf and 
MEK is the best characterized example of Ras-dependent 
signaling and this activation is clearly required for the 
transformation of rodent fibroblast, because the expression 
of the dominant-negative version of MEK, blocks the 
transformation by Ras (4). ERK1/2 phosphorylate multiple 
substrates, including transcriptional activators inducing or 
suppressing transcriptional activation of physiological 
target genes (5). Some of the targets of ERK1/2 are 
transactivators that affect the expression and the post-
translational modifications of the AP-1 factors (6). 
Furthermore, ras activates the JNK family of kinases and 
the phosphatidyl-inositol 3-Kinase pathway through 
different mechanisms (6, 7). Therefore multiple 
mechanisms account for the effects of Ras in the 
regulation of multiple physiological processes, through 
signal transduction pathways, leading to changes in AP-1 
activity. 
Mouse multistage carcinogenesis protocols include 
treatment of the mouse skin at the primary step of initiation 
with chemical carcinogens which result in mutations of Ha-
ras at specific codons that activate its transforming 
properties (8). Other changes in Ha-ras activity result from 
its amplification. This is seen in squamous and spindle 
tumors but not in benign papillomas, suggesting that 
quantitative changes of Ha-ras also affect neoplastic 
development, though in different ways than qualitative 
modifications (9). 
The alterations in Ha-ras clearly correlate with an 
increase in mitogenic signaling, represented by elevated 
JNK and ERK activities in cells cycling in serum (10, 11). 
These signals are related to elevated AP-1 activity at late 
stages of progression. These signals can be reproduced 
partially if a human allele of Ha-ras is introduced in 
squamous cell carcinoma cells. Similarly they can be 
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Figure 1. Suppression of signaling pathways in cells derived from the mouse skin. A) PDVC57 cells have an elevated content of mutant Ha-ras resulting in 
activation of both ERK-1 and ERK-2 isoforms of MAP kinases. Activation of ERKl/2 in PDVC57 is effectively suppressed by PD98059 during growth in 
serum. In PDV cells transfected with a transforming allele of human Ha-ras, ERKl/2 activity is elevated and is suppressed by PD98059 to the same extent as 
in PDVC57, suggesting the direct contribution of Ha-ras to this signaling cascade; B) In A5 spindle carcinoma cells, the expression of the dominant negative 
ATF-2 is sufficient to induce reversion to a flat fibroblastic morphology. This effect is simtiar to what was observed by treating A5 with PD98059 where 
morphological reversion is also evident. The suppression of ERKl/2 activities in A5 is more refractile to inhibition by PD98059 since these cells have 
sustained ERKl/2 activity when growing instead of cycling conditions. 
inhibited by small synthetic inhibitors of the mitogen -
activated protein kinase cascade (11,12). 
2. JNK Signaling is Increased in Cells Derived from Mouse Skin 
Tumors 
In experiments with tumor formation in c-fos -I- mice there 
was no progression to malignancy, whereas the control c-fos 
+/+ mice develop tumors, suggesting that AP-1 activity has 
an oncogenic role and is required for malignant progression 
in vivo (13). 
In the cell lines representing the multistage model of 
mouse skin carcinogenesis the expression of Fos and Jun 
family members is increased. Fos and Jun protein levels are 
most clearly elevated in the spindle carcinoma cells and less 
so in squamous cell carcinoma and some papilloma cell lines 
(10). This increase affects AP-1-DNA-binding activity and 
transactivation. It has been well - established that AP-1 
transcriptional activity is subject to regulation by signal 
transduction cascades of the JNK pathway, which is con­
trolled by Ha-ras (6). 
Investigations of the JNK pathway, using phosphospecific 
antibodies and solid phase kinase assays, showed that JNK 
activity also gradually increases during skin tumor 
progression, thus offering an explanation for the increased 
AP-1 transactivation. These results highlighted, for the first 
time, that, in the mouse skin carcinogenesis model cell lines, 
Ha-ras activation leads to considerable up-regulation of AP-1 
activity and also contributes to tumorigenesis, by mechanisms 
such as the regulation of metalloprotease secretion and 
activity (14). 
3. ERKl/2 Signaling in the Mouse System: the Role of Ha-ras 
In fibroblasts transformed by ras and Raf-1, ERKl/2 are 
necessary for transformation and anchorage-independent 
growth (15, 16). Epithelial cells are less susceptible to 
transformation by oncogenes than NIH3T3 or Rat-1 cells, ras 
and Raf-1 mutants efficiently transform NIH3T3 cells but 
only ras mutants induce transformation and growth in soft 
agar of rat intestinal epithelial cells (RIE) and human 
mammary epithelial cells (17). Therefore, constitutive 
activation of Raf/MEK/ERK signaling is not a sufficient cause 
for transformation of RIE (17). This evidence suggests that 
Raf/MEK/ERK-independent pathways could be largely 
responsible for epithelial cell transformation (18). 
ERKl/2 phosphorylation showed, like JNK1/2 activity, a 
progressive increase from papilloma to the squamous ahd 
spindle cell lines, implying that both types of kinases are 
involved in malignant progression of mouse skin tumors (10, 
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11). Additionally, these results suggest that, in the cells 
derived from the mouse system, a convergence of multiple 
signals arise from Ha-ras to different downstream effectors. 
Balmain et al have shown previously that a reduction in the 
ratio between normahmutant Ha-ras is associated with 
increased tumorigenicity in squamous cell carcinomas (19). 
The PDV cell line represents a rare transformant originally 
isolated by Fusening et al (20) after treatment of epidermal 
cell cultures from newborn mice with the carcinogen DMBA. 
Karyotypic analysis of PDV cells has indicated the presence 
of three copies of chromosome 7 (21), on which the H-ras 
gene is located. Analysis at the DNA level has shown that 
normal and mutated Η-ras alleles are expressed at a ratio of 
2:1, which corresponds to the relative gene dosage (19). PDV 
cells, when injected into adult C57B1 syngeneic mice, give rise 
to squamous carcinoma at only one of the eight sites of 
injection (20, 21). A cell line derived from this tumor 
(PDVC57 cells) had a more heterogenous morphology, with 
an increased number of giant cells and was also more strongly 
tumorigenic on reinjection into adult syngeneic mice, giving 
rise to carcinomas at all 5 injection sites (19). Analysis by 
Southern blotting for the presence of the mutant Η-ras gene 
has shown that the ratio of the mutant:normal Η-ras genes 
had changed from 1:2 to 2:1 (19). PDVC57 are 8-fold more 
invasive and secrete 2-fold more type IV collagenase than 
PDV. Evidence that PDVC57 are more tumorigenic, 
chemotactic and invasive than PDV suggests that tumor 
progression and invasiveness is, at least to some extent, 
dependent on the normahmutant Η-ras ratio (22). 
ERKl/2 phosphorylation in PDVC57 is related to the 
endogenous status of Ha-ras oncogene since it can be inhibited 
by the MEK-1 inhibtor PD98059. To correlate ERK activity 
directly to the levels of Ha-ras in PDVC57 cells, which contain 
increased levels of mutant Ha-ras when compared to PDV, a 
transfection assay was performed. A transforming allele of 
human Ha-ras was introduced into PDV cells (23; Figure 1A). 
ERKl/2 phosphorylation in PDV Ras clones was indicative of 
the Ha-ras-dependent activation of ERKl/2 in these cells (11). 
Therefore in these cells derived from an in vivo system, Ha-ras 
controls ERK activity. This evidence is related to previously 
published results, where a transforming ras allele introduced 
into swiss cells induced ERK activation (24). 
Given that PDVC57 has more malignant characteristics 
than PDV, our findings in PDVRas clones imply that ERKl/2 
activation may play a role in the degree of agressiveness 
during the squamous stage of mouse skin carcinogenesis. In 
order to find out if the ras/MEK/ERK pathway is required for 
the manifestation of tumorigenic properties of the PDVC57 
cells and PDVRas tranfectants, we used a pharmacological 
approach with a MEK-1 inhibitor, PD98059. The ability of 
cells to form colonies and grow in an anchorage -
independent manner, was inhibited after treatment with 
PD98059, implying that the proliferation and tumorogenicity 
of squamous carcinomas of mouse skin are ras/MEK/ERKl/2 
pathway-dependent (11; Figure 1A). 
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Figure 2. The activity of TAM-67 in FBR v-fos transformed fibroblasts that 
is associated with reversion. This is a schematic representation of the 
possible mechanism that might interfere with transactivation in FBR v-fos 
transformed fibroblasts by TAM-67 (29). According to Brown et al (29) a 
quenching mechanism is quite possible in the case of rat embryo cells 
whereas Angel et al (40) and Ochler et al (41) suggest a squelching 
mechanism for P9 cells. 
4. Inhibition of Transformation by Dominant Negative Mutants 
The Fos and Jun family members are downstream effectors of 
growth factor and stress signal transduction pathways (6). 
These transactivators receive multiple signals from the 
outside of the cell and translate them into altered gene 
expression. The fos and Jun family members are central to 
the regulation of many physiological pathways, including 
those controlling cell proliferation and growth, and behave as 
either transactivators or transcriptional repressors, depending 
on the type of extracellular signal and its context. 
Inhibition of AP-1 activity by the use of deletion mutants of 
Fos and Jun proteins, such as the naturally occuring form of 
fosB, has been documented. The alternatively-spliced form of 
fosB, DfosB, is a dominant negative inhibitor of AP-1 activity 
(25, 26 ). Other studies have used dominant negative-mutants 
of c-Jun to inhibit transformation by various nuclear and 
cytoplasmic oncogenes (26 - 29). Lloyd et al, (27) used a v-jun 
deletion mutant fused to the LexA bacterial moiety, resulting 
in a chimera that effectively suppresses ras transformation of 
fibroblasts. The dominant negative N-terminal deletion 
mutant of c-Jun, TAM-67, can effectively suppresses the 
effects of transformation by nuclear oncogenes such as SV40, 
Jun and Fos, and by cytoplasmic oncogenes, such as ras and 
Raf-1 (27,28). TAM-67 also reverts transformation by FBR v-
fos oncogene (29). Fibroblasts transformed whith this 
oncogene are refractile and very invasive (30,31). Expression 
of TAM-67 in FBR cells results in the reappearrence of actin 
stress fibers and suppresses their invasive behavior (29; Figure 
2). In squamous cell carcinoma A431 line, the expression of 
TAM-67 inhibits EGFR-induced cytoskeletal changes (32). 
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Therefore in various cell contexts, TAM-67 is a very potent 
dominant negative inhibitor of many of the physiological 
phenomena associated with the transformed phenotype. The 
activity of TAM-67 in tissue culture cells might be through a 
quenching mechanism, where it dimerises with endogenous 
Jun or Fos proteins resulting in the partial exclusion of those 
proteins from AP-1 sites, thus preventing normal recruitment 
of the transcriptional activation machinery components 
(Figure 2). 
In the mouse skin carcinogenesis model system, ATF-2 
protein is highly expressed in later stages (10). ATF-2 
overexpression by spindle carcinoma cells at a late stage of 
malignant progression implies that this transactivator might 
have a positive effect on the AP-1 activity. Therefore it was 
considered that ATF-2 might be a central element in the 
maintenance of the spindle phenotype. Transfection of 
spindle cells with dominant negative ATF-2 mutant (kindly 
provided by Hans van Dam), lacking the N-terminal 
phosphorylation sites targeted by SAPK/JNK signaling, 
caused a reversion of the spindle morpholgy, decreased cell 
proliferation, and inhibited anchorage-independent growth 
(33; Figure IB). Based on these results it would appear that 
ATF-2 is a central determinant of many of the morphological 
and genotypic changes occuring during tumor progression in 
the mouse skin epidermis. 
Therefore there is a large body of evidence that dominant 
negative mutations in AP-1 family members can inhibit 
transforming signals, initiated by oncogenes acting at diverse 
signal transduction pathways, in fibroblasts and epithelial cells 
Conversely, revertant v-fos, transformed fibroblasts are 
resistant to the action of multiple oncogenes 
Discussion 
J. The Mouse Multistage Skin Carcinogenesis System and 
Possible Applications to Therapy 
In the cells derived from the mouse model of skin carci­
nogenesis there is now some evidence that the activity of both 
the JNK and ERK signaling cascades is increased in the later 
stages of tumor progression (10,11). These results suggest an 
in vivo co-operative phenomenon between the two modules, 
which could increase mitogenic signaling for proliferation. It 
is possible that the action of both pathways is necessary for 
tumor progression. Increased JNK and ERK signaling might 
be the consequence of elevated constitutive Ras activity, 
resulting from Ha-ras mutation and/or amplification. Besides 
the activation of the JNK and ERK signaling cascades, 
ectopic ras expression in epithelial cells also results in 
morphological changes. Transforming ras introduced into 
human mammary epithelial and MDCK cells has been 
reported to induce epithelial-mesenchymal transition, 
resulting in a fibroblastic phenotype (34-36). Signaling by 
transforming Ras leads to a reduction in Rac activity: 
Raf/MEK/ERK signaling down-regulates Tiam-1, an 
exchange factor for Rac, thus down-regulating Rac activity 
but increasing Rho activity resulting in EMT (37). 
Inhibition of JNK and ERK signaling can be achieved 
through the introduction of dominant negative mutants, or by 
the use of chemical inhibitors. The use of the MEK-1 
inhibitor PD98059 has been documented to reverse v-Ki-ras 
transformation and to inhibit growth under anchorage 
independence (38). In the A5 mouse cell line, treatment with 
PD98059 resulted in partial reversion of the phenotype, from 
spindle towards a flat fibroblastic phenotype, and also 
supressed anchorage-independent growth (Figure IB). 
Therefore ERKl/2 activities are necessary for anchorage-
independent growth, but blocking them is not sufficient to 
fully reverse the spindle phenotype to an epithelial 
morphology. This pharmacological inhibition of ERK 
activation suggests the importance of ERKl/2 signaling in 
cancer, and indicates possible therapeutic value. 
Recent data concerning MEK-1 inhibitors also 
demonstrated that Raf/MEK/ERK signaling is required for 
the proliferation of other cancer epithelia. In mouse 
mammary cancer epithelial cells, ERKl/2 phosphorylation, 
which is specifically inhibited by PD98059, could be 
correlated with the EGF-dependent growth and proliferation 
(39). In mice injected with human or mouse colon carcinoma 
cells, tumor formation could be abrogated by the MEK-1 -
specific inhibitor PD184352, which resulted in a reduction in 
ERKl/2 phosphorylation, tumor volume and invasive index 
(38). 
In conclusion, the inhibition of Raf/MEK/ERK signaling in 
two different mouse experimental cancer models significantly 
affected many parameters of tumor development. Since 
models are thought to represent the complex process of 
human tumor formation, which is also characterized by 
multiple changes leading to malignant progression, our results 
are for special interest: therapeutic strategies that interfere 
with ras signaling might be effective against human epithelial 
tumors. 
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